Flavoxate
| Flavoxate
| |
| Systematic (IUPAC) name | |
| 2-(1-piperidyl)ethyl 3-methyl-4-oxo-2-phenyl-chromene-8-carboxylate | |
| Identifiers | |
| CAS number | |
| ATC code | G04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C24H25NO4 |
| Mol. mass | 391.46 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Flavoxate | |
|
Articles | |
|---|---|
|
Most recent articles on Flavoxate | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Flavoxate at Clinical Trials.gov Clinical Trials on Flavoxate at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Flavoxate
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Flavoxate Discussion groups on Flavoxate Directions to Hospitals Treating Flavoxate Risk calculators and risk factors for Flavoxate
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Flavoxate | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Flavoxate is an anticholinergic with antimuscarinic effects. Its muscle relaxant properties may be due to a direct action on the smooth muscle rather than by antagonizing muscarinic receptors.
Clinical uses
Flavoxate is used to treat urinary bladder spasms. It is available under the trade name Urispas (Paladin),Uritac by El Saad company in Syria, or under the name Bladderon by Nippon Shinyaku of Japan.
Flavoxate HCl is indicated for symptomatic relief of interstitial cystitis, dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.
Adverse Reactions
The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency.
Nausea, vomiting, dry mouth vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness. tachycardia and palpitation. urticaria and other dermatoses, eosinophilia and hyperpyrexia, increased ocular tension, blurred vision, disturbance in eye accommodation and dysuria.
Contraindications: Flavoxate HCl is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.
Sources
- Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
- Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies